Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05704725 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)
A Phase 3 study of Chorioretinal Vascular Disease, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 49
- Enrollment target
- 4
- Study locations
NCT05704725 is a Phase 3 study of Chorioretinal Vascular Disease that has completed, run by Amgen. The registered enrollment target is 49 participants. The trial reports 4 study locations across 1 state.
The verdict
NCT05704725, a Phase 3 study of Chorioretinal Vascular Disease, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 49 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary objective of this study is to is to assess the ability of retina specialists to successfully administer, via an intravitreal (IVT) injection, a 2 mg dose of ABP 938, using the ABP 938 aflibercept prefilled syringe (PFS), compared to a 2 mg dose of aflibercept using the aflibercept PFS.
Conditions Studied
Interventions
- DRUG Aflibercept
- DRUG ABP 938
Study Locations (4)
Texas
- Retina Consultants of Texas - Austin Retina - Austin
- Retina Consultants of Texas - Bellaire Retina Center - Bellaire
- Retinal Consultants of Texas - San Antonio Retina Center - San Antonio
- Retina Consultants of Texas - The Woodlands Retina Center - The Woodlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2023-01-23 |
| Est. Completion | 2023-03-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05704725
The ClinicalTrials.gov registry entry for NCT05704725 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chorioretinal Vascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Aflibercept is the first listed.
NCT05704725 reports 4 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05704725 about?
NCT05704725 is a clinical study titled "A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)". The primary objective of this study is to is to assess the ability of retina specialists to successfully administer, via an intravitreal (IVT) injection, a 2 mg dose of ABP 938, using the ABP 938 aflibercept prefilled syringe (PFS), compared to a 2 mg dose of aflibercept using the aflibercept PFS.
What is the current status of trial NCT05704725?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 49 participants. The study started on 2023-01-23. Estimated completion is 2023-03-24.
What conditions does trial NCT05704725 study?
This clinical trial studies the following conditions: Chorioretinal Vascular Disease.
What interventions are being tested in trial NCT05704725?
The interventions under investigation include: Aflibercept (DRUG), ABP 938 (DRUG).
Who is sponsoring clinical trial NCT05704725?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05704725 being conducted?
This trial has 4 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.